![](https://cdn.cancerletter.com/media/2023/04/14014144/Carlos-L-Arteaga_square.png)
![](https://cdn.cancerletter.com/media/2023/04/14014144/Carlos-L-Arteaga_square.png)
The Susan G. Komen organization has awarded a $600,000 research grant to Carlos Arteaga, director of the Harold C. Simmons Comprehensive Cancer Center and associate dean of oncology programs at UT Southwestern Medical Center.
The grant to Arteaga is part of a $62 million investment by the Komen organization for research on drug resistance, triple negative breast cancer, and new treatments such as immunotherapies, as well as funding to reduce cancer health disparities.
Arteaga will study how estrogen receptor-positive breast cancers become hormone-independent and develop resistance to current anti-estrogen therapies. The research could lead to more precise treatment plans for breast cancer patients, potentially involving combinations of drug therapies to prevent the development of drug resistance.